GSK Consumer Healthcare announces availability of OTC children's Flonase Allergy Relief
During the past 20 years, the number of children suffering from allergies has doubled, and reports show that allergies now affect an estimated 40% of children nationwide. A recent survey commissioned by the makers of Children's Flonase Allergy Relief revealed that a majority of parents of young children with seasonal allergies tend to limit their children's time outdoors during allergy season. But this spring, parents can let their children play outside with confidence with the launch of Children's Flonase Allergy Relief.
Available without a prescription, Children's Flonase is an over-the-counter (OTC) nasal spray approved to offer relief of allergy symptoms including runny nose, sneezing, itchy nose, congestion, and itchy, watery eyes. Children's Flonase is a safe, non-habit forming way for children ages four and older to get relief from their nose- and eye-related allergy symptoms. Its active ingredient, fluticasone propionate, has been the No. 1 pediatrician-prescribed nasal allergy medicine for more than 5 years.
The survey of more than 1,000 parents of children (ages 4–11) with allergies provides insights into the challenges of helping to manage their children's symptoms. The results found that 67% of parents have limited their child's time outside during allergy season, and with so many treatment options, 38% of parents said they find it difficult to pick an OTC allergy medicine.
"I see a lot of parents come in whose children are suffering from seasonal or year-round allergies," said Rebecca Newman, a Chicago-area pediatrician with 25 years of practice experience and mother of two boys. "Parents often make accommodations in their children's daily activities, like limiting their time spent outdoors. What they don't realize is that keeping children in a sterile environment does not guarantee that they'll stay allergy-free, and there are products available that block allergy triggers so children can continue enjoying their favorite activities."
Children's Flonase works differently from single-ingredient antihistamines, because it blocks six allergic substances instead of just one. It reduces inflammation and relieves allergy symptoms caused by pollen, mold spores, dust mites and pet dander.
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance